Re "
...newest (ex-big four bank) board director should be able to bring her expertise to bear... "
I think we'll find Ms Cobley is not quite
EX-big four
@irenekwshiu., although (seemingly strangely) I'm even more in agreeance with your conclusion for that reason.
Which is what IMO makes her appointment to the Mesoblast Ltd Board of Directors (albeit non-executive) all the more interesting to me.
Note from the exract below Ms. Cobley's current Board-level commercial commitments globally, apart from CommBank itself, as at 29 May 2025. I've deliberately excluded her various past banking services commitments because they're...well.. past. (Link
here).
That's right. There
aren't any, apart from Mesoblast Limited. Note also the limited number of entities (social/ cultural/ commercial) of all kinds/ forms over which her attention is now split i.e. in May 2025.
Now think back & remember the decision that Dr Philip Krause, then the immediate past-incumbent Deputy Director, Office of Vaccines Research & Review, CBER, FDA made on March 24, 2022. (Link
here).
Dr Krause, like Ms Cobley, could have taken his unique productive skills/ knowledgebase/ contacts anywhere he liked. Certainly, to any major biopharma corporation. In. The. World. Dr Krause didn't want to sit on his hands. I'm certain Ms Cobley is the same, in that respect.
Name a market price for the value of that skillset etc. Name a market price for the value of the marketability of that skillset etc to a cutting edge biotech corporation in an increasingly volatile world.
And they both just 'coincidentally' ended up in lil'' ole Mesoblast. Huh.
Food for thought.
All good
GLTALTH
(20min delay)